- Home
- BBBY vs MYGN Comparison
BBBY vs MYGN Comparison
Compare BBBY & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBBY
- MYGN
- Stock Information
- Founded
- BBBY 1971
- MYGN 1991
- Country
- BBBY United States
- MYGN United States
- Employees
- BBBY N/A
- MYGN N/A
- Industry
- BBBY
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BBBY
- MYGN Health Care
- Exchange
- BBBY Nasdaq
- MYGN Nasdaq
- Market Cap
- BBBY 502.9M
- MYGN 423.1M
- IPO Year
- BBBY N/A
- MYGN 1995
- Fundamental
- Price
- BBBY $9.89
- MYGN $6.61
- Analyst Decision
- BBBY
- MYGN Hold
- Analyst Count
- BBBY 0
- MYGN 13
- Target Price
- BBBY N/A
- MYGN $13.50
- AVG Volume (30 Days)
- BBBY 2.5M
- MYGN 1.5M
- Earning Date
- BBBY 10-23-2025
- MYGN 11-06-2025
- Dividend Yield
- BBBY N/A
- MYGN N/A
- EPS Growth
- BBBY N/A
- MYGN N/A
- EPS
- BBBY N/A
- MYGN N/A
- Revenue
- BBBY $1,128,578,000.00
- MYGN $832,900,000.00
- Revenue This Year
- BBBY N/A
- MYGN $0.17
- Revenue Next Year
- BBBY $11.56
- MYGN $6.19
- P/E Ratio
- BBBY N/A
- MYGN N/A
- Revenue Growth
- BBBY N/A
- MYGN 3.83
- 52 Week Low
- BBBY $3.54
- MYGN $3.76
- 52 Week High
- BBBY $12.24
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- BBBY N/A
- MYGN 64.60
- Support Level
- BBBY N/A
- MYGN $5.78
- Resistance Level
- BBBY N/A
- MYGN $7.05
- Average True Range (ATR)
- BBBY 0.00
- MYGN 0.34
- MACD
- BBBY 0.00
- MYGN 0.07
- Stochastic Oscillator
- BBBY 0.00
- MYGN 75.82
About BBBY Bed Bath & Beyond Inc.
Bed Bath & Beyond Inc is an ecommerce-focused retailer with an affinity model that owns or has ownership interests in various retail brands, offering a comprehensive array of products and services that enable its customers to enhance everyday life through quality, style, and value. The Company currently owns Bed Bath & Beyond, Overstock, buybuy BABY, and other related brands and websites as well as a blockchain asset portfolio.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.